National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA.
Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA.
Arch Toxicol. 2022 Nov;96(11):3077-3089. doi: 10.1007/s00204-022-03347-6. Epub 2022 Jul 26.
Many nitrosamines are recognized as mutagens and potent rodent carcinogens. Over the past few years, nitrosamine impurities have been detected in various drugs leading to drug recalls. Although nitrosamines are included in a 'cohort of concern' because of their potential human health risks, most of this concern is based on rodent cancer and bacterial mutagenicity data, and there are little data on their genotoxicity in human-based systems. In this study, we employed human lymphoblastoid TK6 cells transduced with human cytochrome P450 (CYP) 2A6 to evaluate the genotoxicity of six nitrosamines that have been identified as impurities in drug products: N-nitrosodiethylamine (NDEA), N-nitrosoethylisopropylamine (NEIPA), N-nitroso-N-methyl-4-aminobutanoic acid (NMBA), N-nitrosomethylphenylamine (NMPA), N-nitrosodiisopropylamine (NDIPA), and N-nitrosodibutylamine (NDBA). Using flow cytometry-based assays, we found that 24-h treatment with NDEA, NEIPA, NMBA, and NMPA caused concentration-dependent increases in the phosphorylation of histone H2A.X (γH2A.X) in CYP2A6-expressing TK6 cells. Metabolism of these four nitrosamines by CYP2A6 also caused significant increases in micronucleus frequency as well as G2/M phase cell-cycle arrest. In addition, nuclear P53 activation was found in CYP2A6-expressing TK6 cells exposed to NDEA, NEIPA, and NMPA. Overall, the genotoxic potency of the six nitrosamine impurities in our test system was NMPA > NDEA ≈ NEIPA > NMBA > NDBA ≈ NDIPA. This study provides new information on the genotoxic potential of nitrosamines in human cells, complementing test results generated from traditional assays and partially addressing the issue of the relevance of nitrosamine genotoxicity for humans. The metabolically competent human cell system reported here may be a useful model for risk assessment of nitrosamine impurities found in drugs.
许多亚硝胺被认为是诱变剂和强效啮齿动物致癌物。在过去的几年中,各种药物中都检测到了亚硝胺杂质,导致药物召回。尽管亚硝胺因其潜在的人类健康风险而被列入“关注队列”,但这种担忧大多基于啮齿动物癌症和细菌致突变性数据,而关于其在人体系统中的遗传毒性数据很少。在这项研究中,我们使用转导了人细胞色素 P450(CYP)2A6 的人淋巴母细胞 TK6 细胞来评估已被确定为药物产品中杂质的六种亚硝胺的遗传毒性:N-亚硝基二乙胺(NDEA)、N-亚硝基乙基异丙胺(NEIPA)、N-亚硝基-N-甲基-4-氨基丁酸(NMBA)、N-亚硝基甲基苯胺(NMPA)、N-亚硝基二异丙胺(NDIPA)和 N-亚硝基二丁胺(NDBA)。通过基于流式细胞术的测定,我们发现 24 小时处理 NDEA、NEIPA、NMBA 和 NMPA 会导致 CYP2A6 表达的 TK6 细胞中组蛋白 H2A.X(γH2A.X)的磷酸化浓度依赖性增加。CYP2A6 代谢这四种亚硝胺也会导致微核频率显著增加和 G2/M 期细胞周期停滞。此外,在暴露于 NDEA、NEIPA 和 NMPA 的 CYP2A6 表达 TK6 细胞中发现了核 P53 激活。总的来说,在我们的测试系统中,六种亚硝胺杂质的遗传毒性强度为 NMPA > NDEA ≈ NEIPA > NMBA > NDBA ≈ NDIPA。这项研究为人类细胞中亚硝胺的遗传毒性潜力提供了新信息,补充了传统测定产生的测试结果,并部分解决了亚硝胺遗传毒性与人类相关性的问题。本文报道的代谢功能完备的人类细胞系统可能是评估药物中发现的亚硝胺杂质风险的有用模型。